Unity Biotechnology Inc. (NASDAQ:UBX) and Eton Pharmaceuticals Inc. (NASDAQ:ETON) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Unity Biotechnology Inc.||N/A||0.00||76.40M||-6.20||0.00|
|Eton Pharmaceuticals Inc.||N/A||0.00||37.23M||-0.86||0.00|
Demonstrates Unity Biotechnology Inc. and Eton Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.
Table 2 provides Unity Biotechnology Inc. and Eton Pharmaceuticals Inc.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Unity Biotechnology Inc.||0.00%||0%||0%|
|Eton Pharmaceuticals Inc.||0.00%||0%||0%|
The Current Ratio and Quick Ratio of Unity Biotechnology Inc. are 15.4 and 15.4 respectively. Its competitor Eton Pharmaceuticals Inc.’s Current Ratio is 5.7 and its Quick Ratio is 5.7. Unity Biotechnology Inc. can pay off short and long-term obligations better than Eton Pharmaceuticals Inc.
Ratings and Recommendations for Unity Biotechnology Inc. and Eton Pharmaceuticals Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Unity Biotechnology Inc.||0||0||1||3.00|
|Eton Pharmaceuticals Inc.||0||0||0||0.00|
Unity Biotechnology Inc.’s upside potential currently stands at 161.85% and an $21 consensus target price.
Insider & Institutional Ownership
Institutional investors owned 37.6% of Unity Biotechnology Inc. shares and 6.6% of Eton Pharmaceuticals Inc. shares. Insiders owned roughly 0.2% of Unity Biotechnology Inc.’s shares. On the other hand, insiders owned about 31.2% of Eton Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Unity Biotechnology Inc.||4.13%||-9.62%||-13.18%||-40.91%||0%||-36.41%|
|Eton Pharmaceuticals Inc.||2.89%||28.2%||19.03%||0%||0%||27.78%|
For the past year Unity Biotechnology Inc. had bearish trend while Eton Pharmaceuticals Inc. had bullish trend.
Eton Pharmaceuticals Inc. beats on 3 of the 5 factors Unity Biotechnology Inc.
Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.